Search for a trial

Podocytes derived from induced pluripotent stem cells as biomarker of disease-causing mutations

1. To evaluate if podocytes directly cultured from the urine, and podocytes derived from induced pluripotent stem cells (iPSCs), can be used to prove causality of the VUS.2. Comparison of results obtained using iPSC-derived and urinary podocytes,…

Towards HOMe-based Albuminuria Screening: an implementation study testing two approaches

Primary Objective: To investigate whether population screening for increased albuminuria among the Dutch population can contribute to the early detection of yet undiagnosed risk factors for renal and cardiovascular diseases in an early stage. For…

The application of induced pluripotent stem cells to predict return of the same kidney disease after transplantation.

Development of a predictive test for r-FSGS at the individual level of a patient and kidney donor with FSGS.

A randomized, open-label, parallel group, two arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy.

The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.

A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients.

This study has been transitioned to CTIS with ID 2024-512579-11-00 check the CTIS register for the current data. Primary:- To evaluate the short-term safety and tolerability of TX200-TR101 from the day of TX200 TR101 infusion within 28 days post…

Optimizing Access Surgery In Senior hemodialysis patients

To compare surgical strategies for vascular access creation in elderly hemodialysis patients.

An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, followed by an open-label extension period of 52 weeks in subjects with autosomal dominant polycystic kidney disease (ADPKD).

Main objective- To characterize the effect of GLPG2737 on growth in total kidneyvolume (TKV) compared to placebo.- To evaluate the safety and tolerability of oral doses of GLPG2737compared to placebo.Secondary objectives: - To characterize the…

A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over, mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on renal (cortical and medullary) oxygenation as determined by BOLD-MRI and renal (cortical and medullary) oxygen consumption as determined by positron emission tomography (PET) using ¹¹C-acetate in patients with type 2 diabetes mellitus and healthy controls.

Despite multifactorial treatment approaches residual risk for the development and progression of DKD remains high and novel therapies to halt renal burden in T2DM are urgently needed. SGLT-2 inhibitors are a relatively recent additions to the…

Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease

The primary objective is to demonstrate that semaglutide delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality compared to placebo, both added to standard-of-care, in subjects with type 2 diabetes and…

Laparoscopic Peritoneal Dialysis Catheter Placement: with or without omental and catheter fixation

Comparison of functional outcome of PD catheters in the two placement techniques.Describing 30 day mortality and short and middle term complications.

A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Anti-body Positive Membranous Nephropathy (aMN) - M-PLACE

PRIMARY OBJECTIVE:To assess the safety and tolerability of MOR202 treatment in subjects with aMNKEY SECONDARY OBJECTIVE:To assess the effect of MOR202 on serum anti-PLA2R antibodies in subjects with aMNSECONDARY OBJECTIVES:1. To assess…

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)

This study has been transitioned to CTIS with ID 2023-503382-29-00 check the CTIS register for the current data. * Evaluate the effect of lumasiran on plasma oxalate in patients who are not on dialysis therapy Cohort B* Evaluate the effect of…

Natriuresis following an acute oral versus IV sodium load in type 2 diabetes patients without CKD: An incretin effect

To assess the timed effects of a matched acute oral sodium load (in the absence or presence of GLP-1 receptor agonist) or an acute intravenous sodium load in T2DM patients with/without renal impairment on urinary sodium excretion after 24h,…

Frailty in uremia: A survey on the effects of CKD 3-5 on physical functioning and -activity, quality of life and nutritional state

The primary objective of the study is to assess the longitudinal effects of differences and changes in renal function at CKD stage 3-5 on physical functioning. The secondary objectives of the study are to assess the longitudinal effects of…